Buvidal

buvidal

Drugs A-Z

Scientific Names: Buvidal® prolonged-release solution for injection

Generic Names: Enwau Generig: Buprenorphine prolonged-release solution for injection

Pre-filled syringe containing a yellowish to yellow clear liquid

Desired Effects:

As it is a slow release formulation effects such as euphoria are thought to be neglible

Side Effects:

Reaction at injection site, drowsiness, respiratory depression (more likely if taken at the same time as other central nervous system depressants)
This medication is not given to an individual to have in their possession: it is always administered by a healthcare professional

Long term risks:

Precipitated opioid withdrawal (if taken too soon after an full opioid agonist), tolerance, accidents/overdose (due to central nervous system depression), serotonin syndrome, liver impairment

Short term risks:

Dependence
Central nervous system depressant, opioid analgesic
Administered by a healthcare professional under the skin (in the buttock, thigh, abdomen or upper arm) either once a week or once a month, with potential for additional doses in between to enable dose optimisation and manage opioid withdrawal symptoms if required.
This medication is not given to an individual to have in their possession: it is always administered by a healthcare professional
To treat opioid dependence
A synthetic mixed opioid that acts on opioid receptors in the brain and also blocks them. Supplied from regulated manufacturers and prescribed to individuals.
As this medication is slow-releasing and always in the possession of and administered by healthcare professionals, the risk of diversion is not thought to be an issue when compared to alternative oral formulations of buprenorphine. Specialist drug treatment services offer a range of services including harm reduction advise and psychosocial support in addition to prescribed interventions such as Buvidal®. However Buvidal® is only a treatment option where the drug treatment service is funded to provide this medication and has trained and competent staff to be able to administer it. In some areas community pharmacies or GP practices may also be able to administer this medication depending on how the local drug treatment services are organised. In case of any issues the relevant prescriber should be contacted. Any adverse events should be reported using the yello card system: https://yellowcard.mhra.gov.uk/
Logo of DAN 24/7
Helplines Partnership Member

Freephone 0808 808 2234
Email [email protected]

Twitter Facebook
Hide
Freephone:
0808 808 2234
Email:
[email protected]